Abbott Raises 2026 Profit Forecast By Boosting Device And Diagnostic Sales
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Abbott reported a stronger-than-expected second quarter, driven by robust sales in its device and diagnostic segments. The company has raised its profit forecast for 2026, reflecting confidence in its performance despite previous market concerns regarding potential impacts from subsidy cuts to the Affordable Care Act.
The increase in Abbott's profit outlook is attributed to the strength in its diagnostics and heart devices, showcasing the company's resilience in the medtech sector. This positive development comes as Abbott continues to navigate the challenges posed by changes in healthcare policy.
Sources
Every quote below is verbatim from the article it is attributed to.
“Abbott raises 2026 profit forecast on strength in diagnostics, heart devices”
Yahoo Finance — Abbott raises 2026 profit forecast on strength in diagnostics, heart devices“Abbott turned in a stronger-than-expected second quarter, allaying market concerns that subsidy cuts to the Affordable Care Act by the Trump administration would hurt medtech firms.”
fierce biotech — <a href="/medtech/abbott-2q-led-strong-devicedx-sales-boosts-26-profit-forecast" hreflang="en">Abbott Q2 led by strong device, diagnostic sales as it boosts profit forecast</a>